Latest News
Circassia Appoints Cathrin Petty to its Board of Directors
OXFORD, UK - 8th February 2010 - Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Cathrin Petty to its Board of Directors. Ms Petty is currently a Special Partner at Vitruvian Partners LLP, a Board member of ICON Plc and a member of the Discovery Investment Board at GSK.
"I am delighted to welcome Cathrin to Circassia," said Sir Richard Sykes, Circassia's Chairman. "Her extensive experience of the pharmaceutical industry and strategic development expertise will prove invaluable as Circassia completes its transition from a start-up company to a late-stage development organisation."
Commenting on her appointment, Cathrin Petty said, "Circassia has made great progress in the short period since it was founded under the leadership of a very strong, experienced management team. I look forward to working with the company as it advances its lead products into the final stages of clinical development and commercialisation."
Cathrin Petty has extensive senior-level experience of the life sciences industry. Prior to her current roles at Vitruvian Partners, she spent 10 years at Apax Partners Worldwide LLP, as a Partner in the Healthcare team working in the US and Europe. Prior to Apax, Ms Petty was a Principal at Schroder Ventures Life Sciences and before that Research Analyst at Schroders Investment Management. Previous directorships include Qualitest Pharmaceuticals, Zeneus Pharma, Xanodyne Inc and Intercell AG. She served as a Non Executive Director at the NHS Strategic Health Authority for Greater London until July 2010. Ms Petty holds an MA in Natural Sciences (Immunology) from Cambridge University and is a post graduate in Management Studies from the Judge Institute, Cambridge.
08 February 2010